Vulvar and vaginal neoplasia in women with inflammatory bowel disease

M.D. Rouvroye, G.J. Tack, C.H. Mom, B.I. Lissenberg-Witte, M.J. Pierik, E.A. Neefjes-Borst, N.K.H. De Boer, M. Lowenberg, A. Bodelier, W.H. Verbeek, E. Schoon, E.M. Witteman, M.A. Herwaarden, C.J. Van der Woude, M. Lutgens, E. Kouw, P.J. Van der Veek, R.W. Van der Hulst, H. Sipkema, L.H.C. NissenP.J. Bus, A.E. van der Meulen, F.H. De Bruijne, L.A. van der Waaij, C.G. Noomen, B. Jharap, S. Schmittgens, J.M. Jansen, F. Hoentjen, M.H.A. Lammertink, G.M.P. Houben, I.M. Minderhoud, G. Dijkstra, B. Oldenburg, M.S.G. Sikkens, S.A. Van Tuyl, A.A. van Bodegraven, W.o.r.k.g.r.p. Dutch, Dutch Workgroup on IBD and Vulvovaginal neoplasia

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)149-155
Number of pages7
JournalDigestive and Liver Disease
Volume52
Issue number2
DOIs
Publication statusPublished - 1 Feb 2020

Keywords

  • cancer
  • cohort
  • epidemiology
  • female genital-tract
  • human-papillomavirus
  • immunosuppressive therapy
  • increased risk
  • inflammatory bowel disease
  • prevalence
  • survival
  • thiopurines
  • trends
  • vulvar or vaginal malignancy
  • SURVIVAL
  • HUMAN-PAPILLOMAVIRUS
  • PREVALENCE
  • CANCER
  • TRENDS
  • Vulvar or vaginal malignancy
  • Immunosuppressive therapy
  • FEMALE GENITAL-TRACT
  • Inflammatory bowel disease
  • THIOPURINES
  • INCREASED RISK
  • COHORT
  • EPIDEMIOLOGY

Cite this